Br J Cancer: The use of proton pump inhibitor PPI affects the survival rate of patients with colorectal cancer

Proton pump inhibitor (PPI) is one of the most commonly used prescription drugs in the world, with a usage rate of 11-30% among all adults
.

However, due to its potential carcinogenic effects and other major health complications, the safety of long-term use of PPI is increasingly being questioned

Proton pump inhibitor (PPI) is one of the most commonly used prescription drugs in the world, with a usage rate of 11-30% among all adults

Previous studies have shown that PPI can change the richness and diversity of the gut microbiota
.

According to evidence from preclinical studies, the intestinal dysbiosis caused by it may lead to the occurrence and development of colorectal cancer (CRC)

Colorectal Cancer This study aims to assess the correlation between the use of PPI and CRC-specific mortality

The results showed that a total of 4746 (14.

0%) patients died, and the aHR (adjusted hazard ratio) of all-cause mortality for PPI users and PPI non-users was 1.

A total of 4746 (14.

The use of PPI is related to the diagnosis of CRC

The use of PPI is related to the diagnosis of CRC

All in all, the results of the study revealed that the use of PPI after the diagnosis of CRC is associated with an increase in all-cause mortality and CRC-specific mortality in patients
.

The use of PPI after the diagnosis of CRC is associated with an increase in all-cause mortality and CRC-specific mortality in patients
.

The use of PPI after the diagnosis of CRC is associated with an increase in all-cause mortality and CRC-specific mortality in patients

Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study.

Leave a message here